<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2490">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128747</url>
  </required_header>
  <id_info>
    <org_study_id>Eonpifcolpadp</org_study_id>
    <nct_id>NCT05128747</nct_id>
  </id_info>
  <brief_title>Effectiveness of Nutritional Program Among Diabetic Patients</brief_title>
  <official_title>Effectiveness of Nutritional Program Intervention for Control of Lipid Profile Among Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyslipidemia is very common in type 2 diabetes mellitus affecting around 72%-85% of diabetic&#xD;
      patients.The exact mechanism of lipoprotein abnormalities in diabetes is not very well&#xD;
      understood. Insulin resistance, rather than hyperglycemia, has been implicated in the&#xD;
      pathogenesis of diabetic dyslipidemia because lipoprotein changes including an increase in&#xD;
      triglycerides (TG), increase in VLDL particles, small dense LDL particles and a decrease in&#xD;
      HDL level have been shown in patients with impaired fasting glucose and impaired glucose&#xD;
      tolerance and T2DM&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertriglyceridaemia(HTG) occurs due to both increased production and decreased clearance,&#xD;
      and it is the most common abnormality of diabetic dyslipidemia. Insulin resistance causes&#xD;
      increased production of VLDL . In addition to increased secretion of VLDL, there is decreased&#xD;
      clearance of VLDL due to decreased hepatic uptake and impaired activity of lipoprotein&#xD;
      lipase.Management of dyslipidemia in patients with diabetes is an important step in the&#xD;
      prevention of cardiovascular disease, the most common cause of death in the diabetic&#xD;
      population. Diabetic dyslipidemia treatments can be divided into non-pharmacological and&#xD;
      pharmacological. Non-pharmacological treatment includes ; medical nutrition therapy, weight&#xD;
      loss, and physical activity. Diabetic patients should increase the intake of plant&#xD;
      stanols/sterols, viscous fiber (legumes, citrus, oats), n-3 fatty acids and decrease the&#xD;
      intake of saturated and trans-fatty acids. American Diabetes Association recommends the&#xD;
      Mediterranean diet or DASH (Dietary Approaches to Stop Hypertension).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>diabetic patients type2 with dyslipidemia</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effectiveness of one of the most common dietary approches;DASH diet in controlling lipid profile in diabetic patients.</measure>
    <time_frame>3-6 months</time_frame>
    <description>number of type 2 diabetic patients will undergo nutritional program to control their lipid profile to improve the insulin sensitivity and follow up the result of the diet by investigations (lipid profile) in duration 3 months .</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Dyslipidemia Associated With Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>group of intervention will receive nutritional program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group of type 2 diabetes on diabetic diet undergo nutritional program (low fat contents) to control the lipid profile (lowering cholesterol profile) in duration of 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group of control will not receive nutritional program</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>group of type 2 diabetes on diabetic drugs without nutritional program to compare their lipid profile with the diabetic patients on nutritional program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DASH diet</intervention_name>
    <description>it will be face to face about the role of nutritional program to control dyslipidemia</description>
    <arm_group_label>group of intervention will receive nutritional program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1-clinical diagosis of type2diabetes 2-clinical diagnosis of hyperlpidemia 3-must be&#xD;
             helpful patient 4-age below 70year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1-insulin dependant diabetes 2- pregnancy 3-heart disease 4- renal disease. 5-pregnancy&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dalia galal mahran</last_name>
    <phone>01007120821</phone>
    <email>daliaym2001@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manal El-sayed Ezz-eldeen</last_name>
    <phone>01005826070</phone>
    <email>manal_ezeldeen@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Jialal I, Singh G. Management of diabetic dyslipidemia: An update. World J Diabetes. 2019 May 15;10(5):280-290. doi: 10.4239/wjd.v10.i5.280. Review.</citation>
    <PMID>31139315</PMID>
  </reference>
  <reference>
    <citation>Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229-34.</citation>
    <PMID>9673301</PMID>
  </reference>
  <reference>
    <citation>Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499-502.</citation>
    <PMID>4337382</PMID>
  </reference>
  <reference>
    <citation>Sharifirad G, Entezari MH, Kamran A, Azadbakht L. The effectiveness of nutritional education on the knowledge of diabetic patients using the health belief model. J Res Med Sci. 2009 Jan;14(1):1-6.</citation>
    <PMID>21772854</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Gehad M Galal</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

